查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1717916

溶小體貯積症市場（按疾病類型、治療類型、治療應用和最終用戶分類）—2025 年至 2030 年全球預測

Lysosomal Storage Diseases Market by Disease Type, Treatment Type, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

溶小體貯積症市場預計到 2024 年將達到 101.7 億美元，到 2025 年將達到 110.1 億美元，到 2030 年將達到 164.9 億美元，複合年成長率為 8.38%。

主要市場統計數據
基準年2024年 101.7億美元
預計2025年 110.1億美元
預測年份 2030 164.9億美元
複合年成長率（%） 8.38%

溶小體貯積症的研究是現代醫學和生物技術的重要前沿領域。這些遺傳性代謝紊亂導致未消化的基材在細胞溶酶體內積累，長期以來一直為臨床和科學帶來挑戰。最近的研究趨勢和技術進步正在提高我們對疾病機制的理解並加速創新治療方法的發展。當全球醫療保健界面臨這種情況時，徹底的市場分析、策略性投資和研究合作的重要性變得更加明顯。

此外，這項深入研究不僅概述了治療方案和診斷方法的現狀，而且還揭示了正在重新定義競爭格局的新興趨勢和變革性轉變。透過嚴格的分析，該報告將成為相關人員尋求駕馭複雜市場動態的重要指南，從突破性的基因療法到傳統的酵素干預，最終旨在改善全球患者的治療效果。

隨著研究人員、臨床醫生和決策者的共同努力，將不斷發展的臨床數據與創新治療方法結合變得前所未有的重要。本報告的總體目標是提供一份權威的藍圖，闡明不斷發展的疾病治療領域中的機會和挑戰，並提供可行的見解，以推進溶酶體儲存症領域的臨床實踐和經濟戰略。

改變溶小體貯積症格局的變革

生物醫學研究和技術創新的最新進展正在大幅改變溶小體貯積症的格局。從歷史上看，治療僅限於安寧療護和症狀管理。然而，如今分子生物學和標靶治療方法的令人興奮的突破正在徹底改變患者護理。這種轉變為精準醫療策略鋪平了道路，該策略可根據個別患者特徵和特定疾病機制量身定做治療方案。

次世代定序和先進影像技術的採用提高了我們在早期階段診斷這些疾病的能力，此時治療性介入可以產生最大的影響。更重要的是，這些技術創新促進了治療模式的轉變。基因治療的整合、酵素替代療法的改進以及造血幹細胞移植的探索共同重新定義了臨床實踐中的護理標準。

此外，新型化合物和治療平台的出現為治療與溶小體貯積症相關的複雜性引入了多方面的方法來應對。這些發展不僅改善了患者的治療效果，也促使人們重新評估市場動態、監管環境和研究管道。從傳統藥物開發到客製化、通路特異性治療方法的演變代表著該領域的向前邁出了一步，為以多學科合作和前所未有的臨床突破為特徵的時代鋪平了道路。

隨著產業的不斷發展，決策者必須跟上這些變革，以便在日益由快速的技術進步和對疾病病理學的更深入了解所定義的市場中策略性地定位自己。

利用市場區隔的洞察來客製化您的市場策略

溶小體貯積症市場的細分提供了對各個子區隔的詳細觀點，這些細分市場在理解市場趨勢和投資潛力方面發揮關鍵作用。在疾病類型方面，我們對法布瑞氏症、高雪氏症、韓特氏症症候群、黏多醣症、尼曼匹克症和龐貝氏症等各種疾病進行了全面的回顧。每種疾病都有不同的臨床症狀和治療挑戰，並且需要不同的診斷和治療方法。

治療方法的評估將分析酵素替代療法（進一步細分和研究，包括阿加糖酶BETA、阿糖苷酶和Glucosidaseα）、基因治療、造血幹細胞移植（分為同種異體移植和自體移植）和基材減少療法之間的動態交互作用。這些治療方法的演變反映了強大的創新管道，其療效和安全性不斷與傳統治療方法進行比較。這種分類分析不僅突顯了可用治療方案的多樣性，而且突顯了每個類別內治療性介入的演變。

此外，為了反映溶小體貯積症對患者的多方面影響，市場根據治療應用進行細分。對心血管疾病、中樞神經系統疾病、血液疾病、肺部併發症和骨骼畸形等領域的分析將使相關人員能夠確定治療性介入能夠提供最大臨床益處和市場機會的領域。了解特定的臨床關注領域和治療應用使公司能夠最佳化研發策略並對重要的健康結果進行基準測試。

最後，一個關鍵的細分要素是最終用戶分析。它研究學術研究機構、生物製藥公司、醫院和專科診所的市場動態。從早期研究到臨床應用，每個環節都是疾病管理網路中獨特的節點。從這些細分參數中獲得的詳細見解可以實現資源的策略性調整，從而指導臨床研究和投資決策，以解決疾病病理學和組織創新能力的細微差別。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 溶小體貯積症的盛行率
      • 疾病早期診斷和治療的趨勢
      • 增加酵素替代療法的使用
    • 限制因素
      • 治療費用高且治療機會有限
    • 機會
      • 治療溶小體疾病的新興個人化醫療方法
      • 溶小體儲積症的基因編輯與基因治療進展
    • 任務
      • 溶小體儲存藥物核准的嚴格法規結構
  • 市場區隔分析
    • 疾病類型：擴展Chaperone療法的研發管線，以應對法布瑞氏症的不同突變情況
    • 應用：由於許多 LSD 的心臟併發症性質嚴重，將溶小體貯積症的應用擴展到心血管系統，
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 溶小體貯積症市場（依疾病類型）

  • 法布瑞氏症
  • 高雪氏症
  • 韓特氏症
  • 黏多醣症
  • 尼曼匹克病
  • 龐貝氏症

7. 溶小體貯積症市場（依治療類型）

  • 酵素替代療法
    • 阿加糖酶BETA
    • 阿糖苷酶
    • Glucosidase酶α
  • 基因治療
  • 造血幹細胞移植
    • 同種異體移植
    • 自體移植
  • 基材還原療法

8. 溶小體貯積症市場（依治療應用）

  • 心血管疾病
  • 中樞神經系統疾病
  • 血液系統疾病
  • 肺部併發症
  • 骨骼畸形

9. 溶小體貯積症市場（依最終用戶）

  • 學術研究所
  • 生物製藥公司
  • 醫院
  • 專科診所

10. 美洲溶小體貯積症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11.亞太溶小體貯積症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲的溶小體貯積症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics,Inc.
  • ArmaGen, Inc.
  • BioMarin Pharmaceutical, Inc.
  • CHIESI USA, Inc.
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Homology Medicines, Inc.
  • Horizon Pharma PLC
  • Idorsia Pharmaceuticals Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics Limited
  • Pfizer Inc.
  • Protalix Biotherapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
  • Zevra Therapeutics,Inc.
Product Code: MRR-DD0700E81E5B

The Lysosomal Storage Diseases Market was valued at USD 10.17 billion in 2024 and is projected to grow to USD 11.01 billion in 2025, with a CAGR of 8.38%, reaching USD 16.49 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 10.17 billion
Estimated Year [2025] USD 11.01 billion
Forecast Year [2030] USD 16.49 billion
CAGR (%) 8.38%

The study of lysosomal storage diseases represents a critical frontier in modern medicine and biotechnology. These inherited metabolic disorders, which result in the accumulation of undigested substrates within cellular lysosomes, have long presented both clinical and scientific challenges. In recent years, enhanced research and technological advances have catalyzed a deeper understanding of disease mechanisms and accelerated the development of innovative therapies. As the global healthcare community confronts these conditions, the importance of thorough market analysis, strategic investment, and collaborative research has become increasingly clear.

Moreover, this detailed examination not only outlines the current state of therapeutic options and diagnostic methods, but it also sheds light on emerging trends and transformative shifts that are redefining the competitive landscape. Through rigorous analysis, the report positions itself as an indispensable guide for stakeholders seeking to navigate complex market dynamics, from groundbreaking gene therapies to traditional enzymatic interventions, ultimately aiming to improve patient outcomes worldwide.

As researchers, clinicians, and decision-makers work together, the integration of evolving clinical data and innovative treatment modalities is more critical than ever. The overarching goal of this report is to deliver an authoritative roadmap that highlights the opportunities and challenges within the evolving disease treatment environment, providing actionable insights tailored to advance clinical practice and economic strategies in the realm of lysosomal storage diseases.

Transformative Shifts Reshaping the Lysosomal Storage Diseases Landscape

Recent advancements in biomedical research and technological innovation have dramatically transformed the landscape of lysosomal storage diseases. Historically, treatments were limited to palliative care and symptom management. Today, however, transformative breakthroughs in molecular biology and targeted therapeutic approaches are revolutionizing patient care. These shifts have paved the way for precision medicine strategies, where treatments are tailored to individual patient profiles and specific pathogenetic mechanisms.

The adoption of next-generation sequencing and advanced imaging techniques has enhanced our ability to diagnose these disorders at earlier stages, when therapeutic interventions can have the most profound impact. More importantly, these innovations have spurred a revolution in treatment paradigms. The integration of gene therapy, improvements in enzyme replacement therapy, and the exploration of hematopoietic stem cell transplants have collectively redefined standard practices in clinical settings.

Furthermore, the emergence of novel compounds and therapeutic platforms has introduced a multi-dimensional approach to managing the complexities associated with lysosomal storage diseases. Such developments have not only improved patient outcomes but have also driven a broader re-assessment of market dynamics, regulatory landscapes, and research pipelines. The evolution from conventional drug development to customized, pathway-specific therapies is emblematic of the sector's forward momentum, paving the way for an era characterized by cross-disciplinary collaboration and unprecedented clinical breakthroughs.

As the industry continues to evolve, decision-makers must stay abreast of these transformative changes to strategically position themselves in a market that is increasingly defined by rapid technological advancements and a deepened understanding of disease pathology.

Key Segmentation Insights for Tailored Market Strategies

The segmentation of the lysosomal storage diseases market provides a granular perspective on the various sub-segments that play a crucial role in understanding market trends and investment potential. From a disease type perspective, the market is comprehensively studied across a spectrum of conditions, including Fabry Disease, Gaucher Disease, Hunter Syndrome, Mucopolysaccharidosis, Niemann-Pick Disease, and Pompe Disease. These conditions, each with distinct clinical manifestations and treatment challenges, require tailored approaches to diagnosis and therapy.

When evaluating treatment modalities, the analysis explores the dynamic interplay between Enzyme Replacement Therapy (which itself is investigated through further subdivisions such as Agalsidase Beta, Alglucerase, and Alglucosidase Alfa), Gene Therapy, Hematopoietic Stem Cell Transplant (divided into Allogeneic Transplant and Autologous Transplant), and Substrate Reduction Therapy. The evolution of these therapies reflects a robust pipeline of innovation, where the efficacy and safety profiles are continually benchmarked against traditional treatment regimens. This segmented analysis not only underscores the diversity of treatment options available but also highlights the evolving nature of therapeutic interventions within each category.

Additionally, the market is segmented based on therapeutic application, reflecting the multifaceted ways in which lysosomal storage diseases affect patients. Analysis across areas such as cardiovascular involvement, central nervous system involvement, hematological disorders, pulmonary complications, and skeletal deformities enables stakeholders to pinpoint where therapeutic interventions yield the highest clinical benefit and market opportunity. By understanding the specific areas of clinical concern and treatment application, companies can optimize their research and development strategies to benchmark significant health outcomes.

Lastly, an important segmentation factor is the end-user analysis. This examines market dynamics across academic and research institutes, biopharmaceutical companies, hospitals, and specialty clinics. Each of these segments represents a unique node in the network of disease management, from early-stage research to clinical application. The detailed insights derived from these segmentation parameters enable strategic alignment of resources, guiding clinical research and investment decisions in a way that addresses the nuances of both disease pathology and organizational capacity for innovation.

Based on Disease Type, market is studied across Fabry Disease, Gaucher Disease, Hunter Syndrome, Mucopolysaccharidosis, Niemann-Pick Disease, and Pompe Disease.

Based on Treatment Type, market is studied across Enzyme Replacement Therapy, Gene Therapy, Hematopoietic Stem Cell Transplant, and Substrate Reduction Therapy. The Enzyme Replacement Therapy is further studied across Agalsidase Beta, Alglucerase, and Alglucosidase Alfa. The Hematopoietic Stem Cell Transplant is further studied across Allogeneic Transplant and Autologous Transplant.

Based on Therapeutic Application, market is studied across Cardiovascular Involvement, Central Nervous System Involvement, Hematological Disorders, Pulmonary Complications, and Skeletal Deformities.

Based on End-User, market is studied across Academic & Research Institutes, Biopharmaceutical Companies, Hospitals, and Specialty Clinics.

Regional Dynamics Driving Market Penetration and Growth

Geographical segmentation reveals distinct regional dynamics that shape the market landscape and inform strategic expansion efforts. In the Americas, a combination of robust healthcare infrastructure, advanced research capabilities, and high investment in clinical trials has yielded significant innovations in the treatment of lysosomal storage diseases. The region is a hotbed of clinical research and regulatory advancements, ensuring rapid patient access to emerging therapies while also providing a supportive environment for biotech startups and established pharmaceutical companies.

Meanwhile, the region encompassing Europe, the Middle East, and Africa presents a diverse and complex market scenario. European countries, in particular, benefit from a mature regulatory framework and strong public-private partnerships that drive research and development in rare diseases. The simultaneous development of regional collaborations and initiatives to address healthcare disparities has spurred the adoption of cutting-edge therapies. In the Middle East and Africa, increasing healthcare expenditures and a growing recognition of the need for advanced diagnostic tools are gradually building the necessary infrastructure to support significant market growth.

The Asia-Pacific region continues to emerge as a strategic growth driver, characterized by rapid economic development and a burgeoning biopharmaceutical sector. This region is notable for its accelerated investment in medical research and infrastructure expansion, leading to faster adoption of innovative treatments. Additionally, a growing patient population combined with increasing awareness about lysosomal storage diseases is elevating market demand. The convergence of these factors creates a unique opportunity for market entrants to tailor their strategies, blending advanced research with region-specific healthcare needs and economic considerations.

Thus, regional insights not only highlight the disparities and opportunities across different geographies but also underscore the importance of a localized approach for market penetration and sustainable growth in the domain of lysosomal storage diseases.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Industry Leaders at the Forefront of Innovation

The competitive landscape in the treatment and management of lysosomal storage diseases is marked by the involvement of several pioneering companies. Industry players such as Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, Inc., and ArmaGen, Inc. are driving venture investments and fuel innovative research pipelines to combat the complexities of these disorders. These organizations, along with BioMarin Pharmaceutical, Inc., CHIESI USA, Inc., and Denali Therapeutics Inc., have made significant inroads by leveraging advanced therapeutic platforms and clinical trial data.

Other standout companies, including Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, and Idorsia Pharmaceuticals Ltd., are investing heavily in translational research, ensuring that discoveries at the bench are seamlessly transitioned into the clinic. The impact of these advancements is further amplified by the strategic partnerships forged with JCR Pharmaceuticals Co., Ltd., Neurogene Inc., and Novartis AG, which contribute to a dynamic ecosystem of innovation and market growth. Moreover, firms like Orchard Therapeutics Limited, Pfizer Inc., Protalix Biotherapeutics Inc., and Sangamo Therapeutics, Inc. are actively involved in developing next-generation therapies that promise to alter the treatment paradigm significantly.

Additional contributions come from Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., and Zevra Therapeutics, Inc. Each of these industry leaders brings unique strengths to the table, from robust financial resources and expansive research capabilities to a deep portfolio of clinical innovations. Their strategic investments in research and development have not only enhanced therapeutic efficacy but also ensured a collaborative approach to addressing regulatory challenges and market uncertainties.

Collectively, these companies are setting new benchmarks in the field of lysosomal storage diseases, driving forward a cycle of continuous improvement and market expansion. Their commitment to addressing unmet medical needs and improving patient outcomes is reshaping the competitive landscape in ways that promise long-term benefits for both investors and healthcare providers alike.

The report delves into recent significant developments in the Lysosomal Storage Diseases Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics,Inc., ArmaGen, Inc., BioMarin Pharmaceutical, Inc., CHIESI USA, Inc., Denali Therapeutics Inc., Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co., Ltd., Neurogene Inc., Novartis AG, Orchard Therapeutics Limited, Pfizer Inc., Protalix Biotherapeutics Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., and Zevra Therapeutics,Inc.. Actionable Recommendations for Strategic Market Positioning

To capitalize on the rapid pace of innovation in lysosomal storage diseases, industry leaders must adopt a proactive and multidimensional strategy. First and foremost, it is essential to invest in research and development initiatives that not only target existing clinical challenges but also explore the potential of emerging therapeutic modalities such as gene therapy and advanced enzyme replacement treatments. Embracing new technologies and integrating big data analytics can streamline clinical trial processes and ensure that therapies are optimized for both efficacy and safety.

Companies should also consider strategic alliances and collaborative research efforts with academic institutions and clinical research organizations. Such partnerships can help bridge the gap between laboratory discoveries and their translation into market-ready products. By sharing resources and expertise, entities can accelerate innovation cycles and reduce the inherent risks associated with developing therapies for rare diseases.

Furthermore, decision-makers need to be nimble in adapting to regulatory changes and aligning their market strategies accordingly. Proactive engagement with regulatory bodies, coupled with a willingness to participate in pilot programs and innovative pricing models, will be critical in addressing market uncertainties and ensuring timely product launches. Investment in robust data collection and outcome measurement systems will enable companies to demonstrably showcase the value of their treatments, thereby gaining an edge over competitors in an increasingly crowded market.

Lastly, it is imperative to maintain a patient-centric approach. Understanding the nuanced needs of different patient demographics and tailoring therapeutic solutions accordingly can significantly boost market penetration. Whether through enhancing patient support programs or investing in community-based initiatives, the alignment of corporate goals with patient well-being will continue to be a key driver of sustainable growth in the field.

By implementing these actionable recommendations, industry leaders can not only navigate the complexities of market volatility but also secure a competitive advantage in a rapidly evolving therapeutic landscape.

Conclusion: Charting a Sustainable Future in Lysosomal Storage Diseases

In conclusion, the landscape of lysosomal storage diseases is experiencing an unprecedented phase of transformation. With advancements in diagnostic technologies and the emergence of innovative therapeutic platforms, the market is poised to not only improve the quality of life for patients but also drive significant returns for investors and stakeholders alike. The multifaceted analysis presented in this executive summary - which spans disease type differentiation, evolving treatment options, therapeutic application, and end-user dynamics - underscores the importance of a detailed and proactive approach in tackling this complex healthcare challenge.

The integration of transformative technologies, strategic regional insights, and a dedicated focus on high-potential market segments forms the cornerstone of future success in this domain. As the competitive landscape becomes more dynamic, it is imperative that industry leaders continue to adapt and innovate, aligning their research and development initiatives with evolving clinical needs and market trends.

Ultimately, the journey toward more effective management of lysosomal storage diseases hinges on the collective efforts of researchers, clinicians, and policymakers. By fostering a culture of innovation and embracing collaborative strategies, stakeholders can ensure that significant progress is not only maintained but accelerated in the coming years. This report offers a comprehensive framework for navigating these challenges and seizing the opportunities that lie ahead, paving the way for a more sustainable and patient-centered future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of lysosomal storage disorders
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Increasing use of enzyme replacement therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs and limiting accessibility
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of personalized medicine approach to treat lysosomal
      • 5.1.3.2. Advancements in gene editing technologies and gene therapies for lysosomal storage disorder
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework for approval of lysosomal storage drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing pipeline of chaperone therapies to address varying mutational profiles in fabry disease
    • 5.2.2. Application: Expanding application of lysosomal storage diseases in cardiovascular Involvement due to the critical nature of cardiac complications in numerous LSDs,
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lysosomal Storage Diseases Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Fabry Disease
  • 6.3. Gaucher Disease
  • 6.4. Hunter Syndrome
  • 6.5. Mucopolysaccharidosis
  • 6.6. Niemann-Pick Disease
  • 6.7. Pompe Disease

7. Lysosomal Storage Diseases Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Enzyme Replacement Therapy
    • 7.2.1. Agalsidase Beta
    • 7.2.2. Alglucerase
    • 7.2.3. Alglucosidase Alfa
  • 7.3. Gene Therapy
  • 7.4. Hematopoietic Stem Cell Transplant
    • 7.4.1. Allogeneic Transplant
    • 7.4.2. Autologous Transplant
  • 7.5. Substrate Reduction Therapy

8. Lysosomal Storage Diseases Market, by Therapeutic Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Involvement
  • 8.3. Central Nervous System Involvement
  • 8.4. Hematological Disorders
  • 8.5. Pulmonary Complications
  • 8.6. Skeletal Deformities

9. Lysosomal Storage Diseases Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biopharmaceutical Companies
  • 9.4. Hospitals
  • 9.5. Specialty Clinics

10. Americas Lysosomal Storage Diseases Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Lysosomal Storage Diseases Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Lysosomal Storage Diseases Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Zevra Therapeutics secures FDA approval for Miplyffa targeting Niemann-Pick Disease Type C
    • 13.3.2. Hanmi Pharmaceutical and GC Biopharma advance next-gen Fabry disease treatment with FDA-cleared once-monthly injection
    • 13.3.3. CENTOGENE and Takeda strengthen global partnership to enhance genetic testing for lysosomal storage disorders
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amicus Therapeutics,Inc.
  • 4. ArmaGen, Inc.
  • 5. BioMarin Pharmaceutical, Inc.
  • 6. CHIESI USA, Inc.
  • 7. Denali Therapeutics Inc.
  • 8. Freeline Therapeutics
  • 9. Homology Medicines, Inc.
  • 10. Horizon Pharma PLC
  • 11. Idorsia Pharmaceuticals Ltd.
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Neurogene Inc.
  • 14. Novartis AG
  • 15. Orchard Therapeutics Limited
  • 16. Pfizer Inc.
  • 17. Protalix Biotherapeutics Inc.
  • 18. Sangamo Therapeutics, Inc.
  • 19. Sanofi S.A.
  • 20. Spark Therapeutics, Inc.
  • 21. Swedish Orphan Biovitrum AB
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Ultragenyx Pharmaceutical Inc.
  • 24. Zevra Therapeutics,Inc.

LIST OF FIGURES

  • FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET MULTI-CURRENCY
  • FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET MULTI-LANGUAGE
  • FIGURE 3. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
  • FIGURE 4. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LYSOSOMAL STORAGE DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LYSOSOMAL STORAGE DISEASES MARKET DYNAMICS
  • TABLE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY FABRY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HUNTER SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY MUCOPOLYSACCHARIDOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY NIEMANN-PICK DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY AGALSIDASE BETA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALGLUCERASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CARDIOVASCULAR INVOLVEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM INVOLVEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY PULMONARY COMPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SKELETAL DEFORMITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 287. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 288. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024